News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
1,775 Results
Type
Article (152)
Company Profile (1)
Press Release (1622)
Section
Business (697)
Career Advice (1)
Deals (107)
Drug Development (322)
Employer Resources (4)
FDA (63)
Job Trends (40)
News (1192)
Policy (109)
Tag
Academia (2)
Adcomms (1)
Alliances (159)
Alzheimer's disease (1)
Antibody-drug conjugate (ADC) (7)
Approvals (64)
Artificial intelligence (2)
Bankruptcy (1)
Best Places to Work (23)
Biotechnology (1)
Brain cancer (1)
Cancer (7)
Career advice (1)
Clinical research (298)
Collaboration (3)
Data (5)
Diagnostics (4)
Diversity, equity & inclusion (1)
Earnings (249)
Employer branding (1)
Employer resources (3)
Events (182)
Executive appointments (2)
FDA (65)
Funding (2)
GLP-1 (3)
Government (8)
Healthcare (25)
Infectious disease (1)
IPO (47)
Job creations (18)
Job search strategy (1)
Layoffs (5)
Legal (6)
Management (1)
Medical device (1)
Medtech (1)
Mergers & acquisitions (59)
Metabolic disorders (1)
Neuroscience (1)
NextGen Class of 2024 (9)
Non-profit (7)
Northern California (6)
Obesity (1)
Opinion (1)
Pancreatic cancer (1)
People (260)
Phase I (53)
Phase II (92)
Phase III (173)
Pipeline (2)
Podcasts (1)
Postmarket research (3)
Preclinical (10)
Prostate cancer (2)
Psychedelics (1)
Rare diseases (2)
Real estate (14)
Recruiting (1)
Regulatory (100)
Research institute (2)
RSV (1)
Series A (2)
Startups (15)
The Weekly (1)
United States (20)
Date
Today (1)
Last 7 days (3)
Last 30 days (5)
Last 365 days (119)
2024 (103)
2023 (146)
2022 (198)
2021 (164)
2020 (146)
2019 (126)
2018 (103)
2017 (107)
2016 (79)
2015 (79)
2014 (74)
2013 (50)
2012 (62)
2011 (65)
2010 (69)
Location
Africa (2)
Asia (54)
Australia (3)
California (9)
Canada (2)
China (1)
Europe (871)
Illinois (1)
Maryland (2)
Massachusetts (5)
New York (1)
Northern California (6)
South America (3)
Texas (1)
1,775 Results for "ipsen".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Drug Development
Gilead, Ipsen Tout Phase III Primary Biliary Cholangitis Data as PDUFA Dates Loom
Gilead Sciences’ primary biliary cholangitis candidate seladelpar and Ipsen’s PBC asset elafibranor both showed encouraging Phase III results Wednesday, as they face looming FDA decision dates.
June 5, 2024
·
2 min read
·
Tyler Patchen
Antibody-Drug Conjugate (ADCs)
Ipsen Inks Potential $1B First-in-Class ADC Deal With Foreseen
In its second antibody-drug conjugate licensing agreement this year, Ipsen has secured exclusive rights to Foreseen Biotechnology’s FS001, which targets a novel antigen expressed across a range of solid tumors.
July 11, 2024
·
1 min read
·
Kate Goodwin
FDA
GENFIT: Historic Milestone Achieved with U.S. FDA Accelerated Approval of Ipsen’s Iqirvo® for Primary Biliary Cholangitis
GENFIT announced the achievement of a historic corporate milestone: the U.S. Food and Drug Administration accelerated approval of Iqirvo1 2 80 mg tablets – as unveiled today by Ipsen – as a first-in-class treatment for PBC in combination with ursodeoxycholic acid in adults with an inadequate response to UDCA, or as monotherapy in patients unable to tolerate UDCA.
June 10, 2024
·
15 min read
FDA
Ipsen, Genfit’s Elafibranor Wins FDA Approval for Primary Biliary Cholangitis
Ipsen and Genfit’s elafibranor will now be marketed as Iqirvo and is the first new medicine approved in nearly a decade for the treatment of the rare liver disease, according to the companies.
June 11, 2024
·
2 min read
·
Tristan Manalac
Business
Ipsen appoints Josep Catllà as EVP, Chief Corporate Affairs Officer
PARIS, FRANCE, 06 June 2024 - Ipsen, a global specialty-driven biopharmaceutical company, announced the appointment of Josep Catllà as EVP, Chief Corporate Affairs Officer, effective August 19, 2024.
June 6, 2024
·
6 min read
Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis
Ipsen (Euronext: IPN; ADR: IPSEY) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Iqirvo® (elafibranor) 80 mg tablets for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults who have an inadequate response to UDCA, or as monotherapy in patients unable to tolerate UDCA.
June 10, 2024
·
17 min read
Press Releases
Ipsen’s Kayfanda® (odevixibat) approved in European Union for cholestatic pruritus in Alagille Syndrome, a rare liver disease
September 24, 2024
·
10 min read
Press Releases
Ipsen receives its second Shingo Prize for operational excellence
October 15, 2024
·
6 min read
Business
Ipsen appoints Keira Driansky as EVP, President of North America
Ipsen, a global specialty-driven biopharmaceutical company, announced the appointment of Keira Driansky as EVP, President of North America, effective May 13, 2024.
May 2, 2024
·
6 min read
Press Releases
Ipsen’s Iqirvo® (elafibranor) approved in the European Union as first new treatment for primary biliary cholangitis in nearly a decade
September 20, 2024
·
11 min read
1 of 178
Next